Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received a consensus recommendation of “Hold” from the seventeen research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.93.

SAGE has been the subject of several research analyst reports. Bank of America initiated coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They set an “underperform” rating and a $5.00 target price for the company. Wall Street Zen lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 7th. Piper Sandler lowered shares of Sage Therapeutics from a “strong-buy” rating to a “hold” rating and reduced their price target for the company from $9.00 to $8.50 in a report on Tuesday, June 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research report on Monday, June 16th. Finally, Canaccord Genuity Group lifted their price objective on shares of Sage Therapeutics from $8.00 to $8.50 and gave the stock a “hold” rating in a research report on Tuesday, June 17th.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SAGE. US Bancorp DE lifted its stake in shares of Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock valued at $2,510,000 after buying an additional 10,116 shares during the period. Amundi acquired a new position in shares of Sage Therapeutics in the 4th quarter valued at about $166,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Sage Therapeutics by 157.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company’s stock valued at $918,000 after buying an additional 103,495 shares during the last quarter. Finally, Picton Mahoney Asset Management grew its position in Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Price Performance

NASDAQ:SAGE opened at $9.20 on Friday. Sage Therapeutics has a one year low of $4.62 and a one year high of $13.47. The company’s 50-day simple moving average is $7.53 and its 200 day simple moving average is $7.24. The firm has a market capitalization of $575.80 million, a P/E ratio of -1.59 and a beta of 0.29.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The firm’s revenue for the quarter was up 78.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.80) EPS. On average, equities research analysts expect that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.